How Many People Take Zepbound? An In-Depth Look at Its Impact

Last reviewed: June 23, 2026

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Zepbound (semaglutide) and tirzepatide-based therapies have become some of the most prescribed medications for weight management in the United States. Since tirzepatide's FDA approval in late 2023, millions of patients have begun treatment, with demand continuing to reshape the weight loss medication landscape. Understanding adoption trends helps patients make informed decisions about their own therapy options.

Understanding GLP-1 Receptor Agonist Adoption Rates

Prescription data shows that tirzepatide and semaglutide have reached critical adoption milestones across American healthcare. By mid-2024, pharmacy networks reported filling hundreds of thousands of GLP-1 prescriptions monthly, with tirzepatide gaining market share due to its dual-receptor mechanism targeting both GLP-1 and GIP pathways. This surge reflects not only increased clinical confidence but also growing patient awareness of these medications' effectiveness for sustainable weight loss.

The rapid uptake has created access challenges, including supply constraints and insurance authorization delays. Many patients turn to compounded versions from licensed 503A pharmacies as an alternative to brand-name medications. PlexusDx compounded tirzepatide injection starts at $249/month and requires no insurance, making it accessible across all 50 states without membership fees or hidden costs.

Why Tirzepatide Therapy Is Becoming the Preferred Choice

Tirzepatide's dual action on GLP-1 and GIPR receptors produces weight loss outcomes that often exceed single-receptor agonists. Clinical trials demonstrated average weight reductions of 20–22% over 68 weeks in patients with obesity, compared to 14–17% with semaglutide alone. This superior efficacy has driven patient demand and influenced prescribing patterns among weight loss specialists and primary care physicians.

Beyond raw weight reduction, tirzepatide users report improvements in metabolic markers, including reduced fasting blood glucose and improved insulin sensitivity. These outcomes have made tirzepatide particularly attractive for patients with concurrent type 2 diabetes or prediabetes. PlexusDx offers both compounded tirzepatide injection and oral formulations, allowing patients to select the delivery method that best fits their lifestyle and preferences.

Demographics and Patient Populations Using GLP-1 Therapy

GLP-1 adoption spans diverse demographic groups, though uptake has been highest among patients aged 40–65 with household incomes above $50,000. Both men and women seek these therapies, though women represent a slightly larger portion of the patient population. Healthcare systems have also expanded access to underrepresented communities, though insurance barriers and awareness gaps remain challenges.

PlexusDx serves patients nationwide regardless of demographic background, income level, or prior insurance status. HSA and FSA accounts are accepted, removing additional financial obstacles. The Precision Peptide Genetic Test ($99 add-on) helps identify individual genetic predispositions across 14 pathways and 49 peptides, enabling personalized dosing strategies that may improve outcomes across all patient populations.

Comparing Compounded and Brand-Name GLP-1 Options

Brand-name Zepbound and Mounjaro command premium prices and depend heavily on insurance coverage or cash-pay arrangements. Compounded tirzepatide from licensed 503A pharmacies offers chemically equivalent active ingredients at lower cost without requiring prior authorization. PlexusDx compounded tirzepatide injection ($249/month flat) and oral tirzepatide ($279/month) provide price certainty—your dose may need to go up, but your price won't.

Both compounded and brand-name formulations contain the same active pharmaceutical ingredients, though sourcing, formulation methods, and delivery systems vary. PlexusDx partners exclusively with licensed 503A compounding pharmacies, never 503B facilities, ensuring pharmaceutical-grade quality and sterile compounding practices. Patients choosing compounded tirzepatide receive the same clinical benefits alongside greater affordability and accessibility.

The Role of Genetic Testing in Personalizing GLP-1 Therapy

Genetic variation in GLP-1 receptor pathways, GIPR signaling, and appetite-regulation genes like MC4R and FTO significantly influence individual therapy response. The PlexusDx Precision Peptide Genetic Test identifies key variants—including GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609—that predict how each patient's body will respond to tirzepatide and other GLP-1 therapies. This precision enables dosing strategies tailored to each person's genetic profile.

Patients completing the genetic test gain insights into their peptide pathways and can work with PlexusDx clinicians to optimize their treatment plan from the start. Rather than following standard dose escalation schedules, personalized dosing based on genetic data may accelerate reaching an effective maintenance dose while minimizing side effects. The test costs just $99 as an add-on after your first month of treatment.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How many people currently use Zepbound or tirzepatide in the U.S.?

An estimated 3–4 million Americans have received prescriptions for tirzepatide or semaglutide-based therapies as of late 2024, with monthly prescription volumes continuing to rise. Exact numbers fluctuate due to supply availability and insurance authorization timelines. PlexusDx has helped thousands of patients access compounded tirzepatide across all 50 states without insurance requirements.

What percentage of weight loss can I expect with tirzepatide?

Clinical trials show average weight reductions of 20–22% over 68 weeks with tirzepatide therapy, though individual results vary based on genetics, lifestyle, and adherence. Genetic predispositions identified through the PlexusDx Precision Peptide Genetic Test can help predict your likely response and guide optimal dosing.

Is PlexusDx compounded tirzepatide covered by insurance?

PlexusDx compounded tirzepatide requires no insurance and is not insurance-dependent, making it accessible nationwide. Tirzepatide injection starts at $249/month flat, and oral tirzepatide starts at $279/month. HSA and FSA accounts are eligible, and all 50 states are served without membership fees.

What are the common side effects of tirzepatide therapy?

Nausea, vomiting, and gastrointestinal discomfort are the most frequently reported side effects, particularly during dose escalation. These typically diminish over time as the body adapts. Genetic testing through PlexusDx may help predict individual tolerance patterns and inform personalized dosing strategies that minimize adverse effects.

How does the PlexusDx Precision Peptide Genetic Test help with tirzepatide therapy?

The test ($99 add-on) analyzes 14 pathways and 49 peptides, including GLP1R, GIPR, FTO, and MC4R variants, to predict your individual response to tirzepatide. This genetic insight allows PlexusDx clinicians to customize your dosing plan and medication selection, improving efficacy and potentially reducing side effects from the start of treatment.

Related Reading

• Fridays Zepbound
• Hims Zepbound
• Form Health Zepbound
• Brello Zepbound

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.